摘要
Functional dyspepsia is a symptom complex characterised by upper abdominal discomfort or pain, early satiety, motor abnormalities, abdominal bloating and nausea in the absence of organic disease. The central nervous system plays an important role in the conducting and processing of visceral signals. Alterations in brain processing of pain, perception and affective responses may be key factors in the pathogenesis of functional dyspepsia. Central serotonergic and noradrenergic receptor systems are involved in the processing of motor, sensory and secretory activities of the gastrointestinal tract. Visceral hypersensitivity is currently regarded as the mechanism responsible for both motor alterations and abdominal pain in functional dyspepsia. Some studies suggest that there are alterations in central serotonergic and noradrenergic systems which may partially explain some of the symptoms of functional dyspepsia. Alterations in the autonomic nervous system may be implicated in the motor abnormalities and increases in visceral sensitivity in these patients. Noradrenaline is the main neurotransmitter in the sympathetic nervous system and again alterations in the functioning of this system may lead to changes in motor function. Functional dyspepsia causes considerable burden on the patient and society. The pathophysiology of functional dyspepsia is not fully understood but alterations in central processing by the serotonergic and noradrenergic systems may provide plausible explanations for at least some of the symptoms and offer possible treatment targets for the future.
机能性消化不良是上面的腹的不快或疼痛,早饱足,马达畸形,当器质性病不在时的腹的膨胀和恶心描述的综合征。中枢神经系统在进行并且处理内脏的信号起一个重要作用。在大脑处理疼痛,感觉和感情方面的回答的改变可以是在机能性消化不良的致病的关键因素。中央 serotonergic 和也不肾上腺素能的受体系统涉及处理马达,感觉并且胃肠道的分泌活动。内脏的超敏性当前在机能性消化不良被认为是为马达改变和腹的疼痛负责的机制。一些研究建议在中央 serotonergic 和可以部分解释一些机能性消化不良的症状的也不肾上腺素能的系统有改变。在自主神经系统的改变可以在在内脏的敏感的马达畸形和这些病人的增加被含有。去甲肾上腺素是在交感神经系统的主要 neurotransmitter,再,在这个系统工作的改变可以在运动机能导致变化。机能性消化不良在病人和社会上引起可观的负担。机能性消化不良的病理生理学充分没被理解,但是在由 serotonergic 和也不肾上腺素能的系统的中央处理的改变可以为症状的至少一些提供貌似合理的解释并且为未来提供可能的治疗目标。
基金
the Health Research Board(Ireland),Science Foundation Ireland through the Alimentary Pharmabiotic Centre and the Wellcome Trust.